ARTICLES BY TYLER MENICHIELLO

  • businessmen handskae-agreement-GettyImages-1483521942
    Considerations For Licensing Platforms From Universities
    6/16/2023

    Even the best platforms and technologies don’t come out of universities IND-ready. Just ask Coeptis Therapeutics, which recently licensed the novel CAR-T platform, SNAP-CAR, from the University of Pittsburgh. Coeptis’ Dave Mehalick, and Dan Yerace discuss the licensing agreement and the growing pains to expect when preparing a new platform for an IND.

Tyler Menichiello NL Headshot v3 Square

Tyler Menichiello

Tyler Menichiello is chief editor of Bioprocess Online, where he interviews biopharma executives and subject matter experts about the industry’s most pressing challenges. He aims to deliver actionable insights for biologics developers and manufacturers. Previously, he spent two years as a clinical research associate at the University of Pittsburgh Medical Center’s (UPMC) Hillman Cancer Center, working on clinical trials for hematological malignancies. He studied biology and journalism at Indiana University of Pennsylvania (IUP). You can connect with Tyler on LinkedIn.